Aug 6 |
Compugen Reports Second Quarter 2024 Results
|
Aug 5 |
Compugen Q2 2024 Earnings Preview
|
Jul 30 |
Compugen receives FDA approval for Phase I trial of solid tumour treatment
|
Jul 29 |
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
|
Jul 23 |
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
|
Jul 16 |
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
|
Jul 12 |
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
|
Jul 10 |
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
|
Jul 2 |
The past three years for Compugen (NASDAQ:CGEN) investors has not been profitable
|
Jun 17 |
Compugen to Present at Upcoming Antibody Industrial Symposium
|